Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension
- 587 Downloads
To the Editor,
We read with interest the article “Single-Center Experience Using Selexipag in a Pediatric Population” by Gallotti et al. . The authors describe their experience with the selective prostacyclin (IP) receptor agonist selexipag in five children with either idiopathic pulmonary artery hypertension (IPAH), or pulmonary hypertension (PH) associated with congenital heart disease (PH-CHD), including one that had single ventricle physiology (failing Fontan, i.e., no PAH by guideline definition). Gallotti et al.  emphasize the need for a thorough evaluation of children with PH, by applying the gold standard cardiac catheterization and as the first line, non-invasive method, transthoracic echocardiography . They also discuss the most frequent pharmacotherapy worldwide, namely to start phosphodiesterase 5 inhibitors (PDE-5i), followed by—or in combination with—an endothelin receptor antagonists (ERA). Pediatric inpatients with PAH, ill-appearing PAH patients, and those...
Compliance with Ethical Standards
Confilct of interest
The authors declare that there was no financial support that might pose a conflict of interest in connection with the submitted article.
Research Involving Human and Animal Participants
This letter does not include any research involving human participants and/or animals.
Informed consent has not been obtained as such consent is not applicable for this article.
- 2.Hansmann G, Apitz C (2016) Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii67–85CrossRefPubMedGoogle Scholar
- 7.Koestenberger M, Apitz C, Abdul-Khaliq H, Hansmann G (2016) Transthoracic echocardiography for the evaluation of children and adolescents with suspected or confirmed pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii14–22CrossRefPubMedGoogle Scholar